Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

"Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

A pair of studies show that Zepbound can help adults with obesity and overweight achieve sustained and meaningful weight loss ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Discover Mounjaro Tirzepatide's impact on obesity in India post its March launch. Get insights on effectiveness against diabetes, hypertension & more.

Note – this is an early press release from the European Congress on Obesity in Malaga, Spain, 11-14 May. Please credit the congress when using this research.* New research to be presented at this year ...

“Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be sustained for up to three years,” Dr. Busetto noted. He added, “Regardless of age ...

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Tirzepatide works by mimicking the glucagon ... current smoker status, and BMI. The analysis identified three patterns of weight-loss trajectories: participants in Group 1 (248) experienced ...

According to a new study, a once-weekly dose of tirzepatide can lead to significant ... either living with obesity (a body mass index, or BMI, over 30) or were overweight (BMI of 27 or higher ...